This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More
by Zacks Equity Research
Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVA
Bristol-Myers (BMY) to Post Q2 Earnings: What is in the Cards?
by Zacks Equity Research
Investors will likely focus on the demand for Eliquis and Opdivo along with incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q2 results. Operating expenses might have jumped.
Healthcare ETFs in Focus Ahead of Q2 Earnings
by Sweta Killa
The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.
Earnings Preview: Bristol Myers Squibb (BMY) Q2 Earnings Expected to Decline
by Zacks Equity Research
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $73.14, marking a -0.81% move from the previous day.
Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RYH
Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $74.53, marking a -0.64% move from the previous day.
Rhythm Pharmaceuticals, Inc. (RYTM) Surges 42.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Exelixis (EXEL) Cabometyx Combo Study Meets Primary Goal
by Zacks Equity Research
Exelixis'(EXEL) late-stage study evaluating the combination of Cabometyx and Opdivo and Yervoy demonstrates significant improvement in progression-free survival at the primary analysis.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?
by Zacks Equity Research
Sector ETF report for RYH
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Biohaven (BHVN) Begins Phase III Study on SMA Candidate
by Zacks Equity Research
Biohaven (BHVN) commenced enrollment in a phase III study to evaluate its muscle-targeted recombinant protein candidate, taldefgrobep alfa, in patients with SMA.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $75.14 in the latest trading session, marking a -1.42% move from the prior day.
Exelixis (EXEL) Collaborates With Ryvu for Cancer Therapies
by Zacks Equity Research
Exelixis (EXEL) teams up with Ryvu Therapeutics to develop novel STING agonist-based targeted cancer therapies.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Exelixis (EXEL) Outperforms Industry in 1H22: What Lies Ahead?
by Zacks Equity Research
Exelixis (EXEL) outperforms the industry in the year so far on Cabometyx performance and pipeline progress.
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed the most recent trading day at $76.84, moving -0.21% from the previous trading session.
Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed the most recent trading day at $78.28, moving -0.53% from the previous trading session.
Sutro Biopharma (STRO) Up 50% on Cancer Treatment Collaboration
by Zacks Equity Research
Sutro Biopharma (STRO) inks a partnership and licensing deal with Astellas Pharma to discover and develop iADCs for cancer patients not responding to existing therapies.
Bristol Myers (BMY) Breyanzi Gets FDA Nod for Label Expansion
by Zacks Equity Research
Bristol Myers' CAR T cell therapy Breyanzi was approved by the FDA for relapsed or refractory large B-cell Lymphoma after one prior therapy.
Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $77.69, marking a +1.49% move from the previous day.
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $76.55, marking a +0.1% move from the previous day.
Iovance (IOVA) Pipeline Aids Growth Amid Lack of Marketed Drugs
by Zacks Equity Research
Iovance (IOVA) is progressing well with the clinical development of its pipeline candidates. It expects to file a BLA with the FDA, seeking approval for its lead candidate to treat metastatic melanoma, this August.
Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FLQL